Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play
William Demant Invest has extended its equity position in GN Store Nord to at least 10%, and whereas the Danish investment firm’s CEO says this move is wholly in line with company strategy, several analysts question the motives behind the purchase.
BY CHRISTIAN BUNDGAARD
William Demant Invest (WDI), majority shareholder of hearing health company Demant, has set something in motion rarely seen on Nasdaq Copenhagen.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.